Exploring the survival curves of independent risk factors for PFS and OS, it was found that patients with clinical staging (IV), number of lymph node metastases (≥12), and lncRNA CASC9 (≥2.38) have shorter PFS. Here, CASC9 is linked to metastatic malignant neoplasm in the lymph nodes.